Xarelto® Lawsuit (MDL 2592) Update: JPML Centralizes MDL in Louisiana
On October 9, 2014, and on behalf of six plaintiffs, Roger Denton of Schlichter, Bogard & Denton, LLP filed a petition with the Judicial Panel on Multidistrict Litigation (JPML) requesting that all federally-filed Xarelto® cases be consolidated for coordinated pretrial proceedings.
On December 4, 2014, a hearing before five federal judges on the Multidistrict Litigation Panel took place regarding the potential Xarelto® MDL in Charleston, South Carolina. During the hearing, counsel for plaintiffs and defendants presented their arguments to the JPML panel as to whether all federally-filed Xarelto® cases should be consolidated and transferred to one district court, as well as the particular district court. After the hearing, the JPML decided to consolidate the federal cases and centralize the Multidistrict Litigation (MDL 2592) in the District Court for the Eastern District of Louisiana before Judge Fallon.
Plaintiffs allege that Xarelto® was introduced in the United States market on July 1, 2011 and is part of a class of drugs called New Oral Anticoagulants (NOACs). This class of NOACs, which also includes Pradaxa® and Eliquis®, has been marketed as the next generation of blood-thinning drugs designed to replace warfarin – which has been on the United States market for more than 50 years. Xarelto® has been widely prescribed to prevent pulmonary embolism and deep vein thrombosis, as well as strokes in patients suffering from atrial fibrillation. However, Xarelto® carries a significant risk of severe, and sometimes even fatal, internal bleeding – and there is no reversal agent available if serious bleeding occurs with Xarelto® use. In addition, Xarelto® has been marketed as a single daily dose pill that does not require the need to measure the blood plasma levels, and thus touted as the more convenient option to warfarin (which does require testing and monitoring).
The Institute for Safe Medication Practices (ISMP) reports that for 2013 the U.S. Food and Drug Administration (FDA) received 680 serious adverse event reports from individuals who alleged to have suffered adverse events while taking the anticoagulant drug Xarelto® (rivaroxaban), while only 528 serious adverse events were received for Pradaxa® (dabigatran). The FDA’s Adverse Event Reporting System (FAERS) remains the cornerstone of postmarket safety surveillance, the mechanism through which most significant drug risks are detected once a drug has been approved and is available on the market.
Schlichter, Bogard & Denton, LLP is a unique law firm that has held numerous leadership positions in national litigations involving dangerous pharmaceutical medications, unsafe medical devices and toxic torts. If you or a loved one suffered serious injury after using Xarelto®, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.
The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.